|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1800 CONCORD PIKE, P.O. BOX 15437 |
Address2 |
|
City | WILMINGTON |
State | DE |
Zip Code | 19850-5437 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 54073-12
|
||||||||
|
6. House ID# 349750000
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Kate Belinski |
Date | 10/20/2021 9:09:31 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act.
H.R. 19 / S. 2164, the Lower Costs, More Cures Act.
H.R. 3749, To amend title XXVII of the Public Health Services Act to expand the availability of coverage for lunch cancer screenings without the imposition of cost sharing.
Issues related to Cures 2.0.
Issues related to drug pricing.
COVID-19 vaccine and therapy development.
Issues related to health equity and clinical trials
Build Back Better Reconciliation Bill
Issues related to drug regulation & approval pathways
S.2911, Seniors Prescription Drug Relief Act
Issues related to value-based arrangements
Oncology Care Model / Oncology Care First
H.R. 1730/S. 670- Speeding Therapy Access Today Act;
H.R. 483/S. 350 - Newborn Screening Saves Lives Act
Diverse and Equitable Participation in Clinical Trials Act Discussion Draft
General issues related to orphan disease drugs;
FDA modernization policy issues;
Reauthorization of newborn screening programs;
Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients;
General issues related to diagnostics for patients with rare diseases
Cancer screening, diagnostics and treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), White House Office, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Susie |
Ahn |
|
|
|
Thad |
Flood |
|
|
|
Katie |
Jones |
|
|
|
Caroline |
Quat |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to Medicare Parts B and D pricing reform, H.R. 3684, S. 2327, Senate
S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act.
Issues related to CMS rulemaking [CMS-4190-F3, CMS-2482-P2].
S. 2614, the NOVEL Act
Medicare Multi-Cancer Early Detection Screening Coverage; H.R. 1946;
H.R. 5260 - Reduced Costs and Continued Cures Act; Build Back Better Act
General issues related to patient access to rare disease therapies, Part B and Part D drugs;
Issues related to home infusion for Part B patients;
Value-based payment arrangements;
Efforts to improve coding, coverage, and access for rare disease therapies;
Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies;
General issues related to telemedicine
Issues related to 340B
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Susie |
Ahn |
|
|
|
Thad |
Flood |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Caroline |
Quat |
|
|
|
Katie |
Jones |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to the 340B drug discount program.
Discussions related to an appropriations hold on funding for a 2014 FDA rule that would move package inserts (PI) from paper to digital form-e-labeling.
FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Susie |
Ahn |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Caroline |
Quat |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
S. 1435, the Affordable Prescriptions for Patients Act.
H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act.
H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act.
Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform
S. 2428, the False Claims Amendments
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susie |
Ahn |
|
|
|
Aaron |
Hunter |
|
|
|
Helen |
Dwight |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to international and corporate tax reform.
Build Back Better Act - Issues related to the Orphan Drug Tax Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susie |
Ahn |
|
|
|
Helen |
Dwight |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |